Disease · MONDO_0005351
anorexia nervosa
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. anorexia nervosa. Diseases, record MONDO_0005351. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005351
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs39
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| OLANZAPINE | CHEMBL715 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ESTRADIOL | CHEMBL135 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| MECASERMIN | CHEMBL1201716 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 3 | Drugs and targets |
| ARIPIPRAZOLE | CHEMBL1112 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TERIPARATIDE | CHEMBL525610 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALENDRONIC ACID | CHEMBL870 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DENOSUMAB | CHEMBL1237023 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DRONABINOL | CHEMBL465 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MELATONIN | CHEMBL45 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ROMOSOZUMAB | CHEMBL2107874 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 39
See all 39 drugsTargets52
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | 5 | D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist; Dopamine receptors; D2 & D3 antagonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 5 | Serotonin (5-HT) receptor antagonist; Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| SLC6A4 | Sodium-dependent serotonin transporter | 4 | Serotonin transporter inhibitor; Sodium-dependent serotonin transporter releasing agent | Phase 2 | https://conductscience.org/library/genes/6532 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 3 | D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; Dopamine receptors; D2 & D3 antagonist | Phase 3 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 3 | Serotonin (5-HT) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 3 | Norepinephrine transporter inhibitor; Sodium-dependent noradrenaline transporter releasing agent | Phase 2 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| AR | Androgen receptor | 2 | Androgen Receptor agonist | Phase 2 | https://conductscience.org/library/genes/367 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 2 | D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1815 | Drugs and targets |
| ESR1 | Estrogen receptor | 2 | Estrogen receptor alpha agonist | Phase 3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
1 to 10 of 52
See all 52 targetsTrials52
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01170117 | Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa | Not applicable | 152 | 2017-08-25 | Anorexia Nervosa | OLANZAPINE | Its record names the disease | ClinicalTrials.gov |
| NCT01406444 | IGF-1 and Bone Loss in Women With Anorexia Nervosa | Not applicable | 148 | 2020-07-17 | Anorexia Nervosa, Osteopenia, Osteoporosis | RISEDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT00088153 | Effects of Anorexia Nervosa on Bone Mass in Adolescents | Phase 2/3 | 110 | 2011-10-10 | Anorexia Nervosa | ESTROGEN | Its record names the disease | ClinicalTrials.gov |
| NCT01121211 | Hormonal Factors in the Treatment of Anorexia Nervosa | Phase 2 | 90 | 2017-04-26 | Anorexia Nervosa, Eating Disorder, Anxiety, Depression | TESTOSTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT00310791 | Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa | Phase 2/3 | 80 | 2013-02-01 | Anorexia Nervosa | ESTROGEN, PRASTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT01301183 | Effects of Anorexia Nervosa on Peak Bone Mass | Phase 3 | 75 | 2021-07-13 | Anorexia Nervosa | ESTRADIOL, MECASERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT01996644 | A Double Blind Clinical Trial of DCS for Food Anxiety | Not applicable | 47 | 2018-03-27 | Anorexia and Bulimia Nervosa | CYCLOSERINE | Its record names the disease | ClinicalTrials.gov |
| NCT00260962 | Olanzapine in the Treatment of Patients With Anorexia Nervosa | Phase 2 | 34 | 2017-04-28 | Anorexia Nervosa | OLANZAPINE | Its record names the disease | ClinicalTrials.gov |
| NCT04128683 | Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa | Early phase 1 | 31 | 2025-04-11 | Anorexia Nervosa | AMISULPRIDE, BROMOCRIPTINE | Its record names the disease | ClinicalTrials.gov |
| NCT03292146 | Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study | Phase 3 | 30 | 2022-10-12 | Bone Density, Bone Loss, Anorexia Nervosa, Eating Disorder, Atypical Anorexia Nervosa | ALENDRONIC ACID, DENOSUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 52
See all 52 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Olanzapine vs Placebo: deaths from any cause | 0 of 75 | 0 of 77 | 152 | NCT01170117 | Trial comparisons |
| Olanzapine vs Placebo: serious adverse events | 16 of 75 | 13 of 77 | 152 | NCT01170117 | Trial comparisons |
| Physiologic Estrogen Replacement vs Placebo: serious adverse events | 12 of 55 | 16 of 55 | 110 | NCT00088153 | Trial comparisons |
| Testosterone vs Placebo: deaths from any cause | 0 of 43 | 0 of 47 | 90 | NCT01121211 | Trial comparisons |
| Testosterone vs Placebo: serious adverse events | 4 of 43 | 1 of 47 | 90 | NCT01121211 | Trial comparisons |
| Active vs Placebo: serious adverse events | 0 of 40 | 0 of 40 | 80 | NCT00310791 | Trial comparisons |
| Rh IGF-1 + Transdermal Estradiol vs Placebo + Transdermal Estradiol: deaths from any cause | 0 of 38 | 0 of 37 | 75 | NCT01301183 | Trial comparisons |
| Rh IGF-1 + Transdermal Estradiol vs Placebo + Transdermal Estradiol: serious adverse events | 7 of 38 | 12 of 37 | 75 | NCT01301183 | Trial comparisons |
| Setraline vs Placebo: serious adverse events | 0 of 20 | 0 of 16 | 36 | NCT01996644 | Trial comparisons |
| Placebo Plus Day Hospital vs Olanzapine Plus Day Hospital: serious adverse events | 0 of 18 | 0 of 16 | 34 | NCT00260962 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials33
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005351
GET https://conductscience.org/api/diseases/v1/MONDO_0005351/drugs?page=2